(HBM) Hudbay Minerals - Ratings and Ratios
Copper, Gold, Silver, Zinc, Molybdenum
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 53.8% |
| Value at Risk 5%th | 81.0% |
| Relative Tail Risk | -8.38% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.13 |
| Alpha | 46.47 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.495 |
| Beta | 1.489 |
| Beta Downside | 1.723 |
| Drawdowns 3y | |
|---|---|
| Max DD | 41.10% |
| Mean DD | 15.31% |
| Median DD | 14.84% |
Description: HBM Hudbay Minerals November 07, 2025
Hudbay Minerals Inc. (NYSE: HBM) is a Toronto-based, diversified mining company operating primarily in North and South America. Its portfolio includes the flagship Constancia copper-gold-silver mine in Cusco, Peru, and it produces copper concentrates (with by-product gold and silver), silver/gold doré, zinc concentrates (with gold), and molybdenum concentrates.
Key operational metrics from FY 2023 show ≈ 260 kt of copper produced, ≈ 1.4 Mt of zinc, and ≈ 0.7 Mt of molybdenum, generating US$1.2 bn of revenue and a free cash flow conversion of roughly 45 %. The company’s exposure to copper prices remains a primary driver, with the ongoing EV-induced demand surge and Peru’s recent fiscal reforms influencing both cost structure and permitting timelines. Debt stands at US$1.1 bn (net-debt to EBITDA ≈ 2.3×), giving it moderate leverage relative to peers.
For a deeper quantitative view of HBM’s valuation and risk profile, a quick scan of the analyst tools on ValueRay could be a useful next step.
HBM Stock Overview
| Market Cap in USD | 5,903m |
| Sub-Industry | Diversified Metals & Mining |
| IPO / Inception | 2009-02-13 |
| Return 12m vs S&P 500 | 47.7% |
| Analyst Rating | 4.50 of 5 |
HBM Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 0.10% |
| Yield on Cost 5y | 0.24% |
| Yield CAGR 5y | -1.71% |
| Payout Consistency | 87.0% |
| Payout Ratio | 2.2% |
HBM Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 39.91% |
| CAGR/Max DD Calmar Ratio | 0.97 |
| CAGR/Mean DD Pain Ratio | 2.61 |
| Current Volume | 3979.2k |
| Average Volume | 5547.4k |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (461.7m TTM) > 0 and > 6% of Revenue (6% = 123.8m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -0.52pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -1.68% (prev 21.29%; Δ -22.97pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 740.1m > Net Income 461.7m (YES >=105%, WARN >=100%) |
| Net Debt (497.1m) to EBITDA (1.28b) ratio: 0.39 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.97 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (396.9m) change vs 12m ago 0.67% (target <= -2.0% for YES) |
| Gross Margin 37.80% (prev 27.13%; Δ 10.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 36.11% (prev 37.05%; Δ -0.93pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 11.48 (EBITDA TTM 1.28b / Interest Expense TTM 75.5m) >= 6 (WARN >= 3) |
Altman Z'' 2.31
| (A) -0.01 = (Total Current Assets 994.3m - Total Current Liabilities 1.03b) / Total Assets 5.92b |
| (B) 0.06 = Retained Earnings (Balance) 332.5m / Total Assets 5.92b |
| (C) 0.15 = EBIT TTM 867.5m / Avg Total Assets 5.71b |
| (D) 1.09 = Book Value of Equity 3.08b / Total Liabilities 2.84b |
| Total Rating: 2.31 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 76.35
| 1. Piotroski 6.0pt |
| 2. FCF Yield 4.96% |
| 3. FCF Margin 15.38% |
| 4. Debt/Equity 0.36 |
| 5. Debt/Ebitda 0.39 |
| 6. ROIC - WACC (= 5.24)% |
| 7. RoE 16.56% |
| 8. Rev. Trend 50.95% |
| 9. EPS Trend 49.22% |
What is the price of HBM shares?
Over the past week, the price has changed by -2.94%, over one month by -3.56%, over three months by +27.69% and over the past year by +64.87%.
Is HBM a buy, sell or hold?
- Strong Buy: 8
- Buy: 8
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the HBM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20.8 | 39.8% |
| Analysts Target Price | 20.8 | 39.8% |
| ValueRay Target Price | 18.4 | 23.9% |
HBM Fundamental Data Overview November 23, 2025
P/E Trailing = 12.8448
P/E Forward = 13.4409
P/S = 2.8612
P/B = 1.875
P/EG = 2.09
Beta = 2.081
Revenue TTM = 2.06b USD
EBIT TTM = 867.5m USD
EBITDA TTM = 1.28b USD
Long Term Debt = 536.0m USD (from longTermDebt, last quarter)
Short Term Debt = 540.9m USD (from shortTermDebt, last quarter)
Debt = 1.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 497.1m USD (from netDebt column, last quarter)
Enterprise Value = 6.40b USD (5.90b + Debt 1.11b - CCE 611.1m)
Interest Coverage Ratio = 11.48 (Ebit TTM 867.5m / Interest Expense TTM 75.5m)
FCF Yield = 4.96% (FCF TTM 317.3m / Enterprise Value 6.40b)
FCF Margin = 15.38% (FCF TTM 317.3m / Revenue TTM 2.06b)
Net Margin = 22.38% (Net Income TTM 461.7m / Revenue TTM 2.06b)
Gross Margin = 37.80% ((Revenue TTM 2.06b - Cost of Revenue TTM 1.28b) / Revenue TTM)
Gross Margin QoQ = 18.83% (prev 32.90%)
Tobins Q-Ratio = 1.08 (Enterprise Value 6.40b / Total Assets 5.92b)
Interest Expense / Debt = 1.62% (Interest Expense 18.0m / Debt 1.11b)
Taxrate = 32.71% (108.1m / 330.5m)
NOPAT = 583.7m (EBIT 867.5m * (1 - 32.71%))
Current Ratio = 0.97 (Total Current Assets 994.3m / Total Current Liabilities 1.03b)
Debt / Equity = 0.36 (Debt 1.11b / totalStockholderEquity, last quarter 3.08b)
Debt / EBITDA = 0.39 (Net Debt 497.1m / EBITDA 1.28b)
Debt / FCF = 1.57 (Net Debt 497.1m / FCF TTM 317.3m)
Total Stockholder Equity = 2.79b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.80% (Net Income 461.7m / Total Assets 5.92b)
RoE = 16.56% (Net Income TTM 461.7m / Total Stockholder Equity 2.79b)
RoCE = 26.10% (EBIT 867.5m / Capital Employed (Equity 2.79b + L.T.Debt 536.0m))
RoIC = 15.09% (NOPAT 583.7m / Invested Capital 3.87b)
WACC = 9.85% (E(5.90b)/V(7.01b) * Re(11.50%) + D(1.11b)/V(7.01b) * Rd(1.62%) * (1-Tc(0.33)))
Discount Rate = 11.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.62%
[DCF Debug] Terminal Value 71.03% ; FCFE base≈319.9m ; Y1≈394.6m ; Y5≈673.2m
Fair Price DCF = 16.82 (DCF Value 6.66b / Shares Outstanding 396.1m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 49.22 | EPS CAGR: 49.11% | SUE: -2.00 | # QB: 0
Revenue Correlation: 50.95 | Revenue CAGR: 2.83% | SUE: -0.91 | # QB: 0
Additional Sources for HBM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle